Relationships between Euglobulin Clot Lysis Time and the Plasma Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1

Summary

The relationships between tissue plasminogen activator (tPA), its fast acting inhibitor (PAI-1) and euglobulin clot lysis time (ELT) were investigated with healthy volunteers’ plasma. Turbidimetric clot lysis assay by the microtiter plate reader was utilized for ELT with a slight modification. Both tPA and PAI-1 showed the significant correlation with ELT. tPA had a significantly positive, not negative, correlation with ELT (R = 0.387, p <0.001). Higher correlation coefficients (R = 0.580, p <0.001 and R = 0.599, p <0.001) were obtained between ELT and total PAI-1 or free PAI-1 than tPA or tPA-PAI-1 complex (R = 0.427, p <0.001). The positive correlation was also obtained between tPA and PAI-1. These data suggest that PAI-1 is a highly important factor for ELT, especially, the amounts of free PAI-1 being the key factor to determine the ELT, which can represent the potential activity of the fibrinolytic system.

Keywords

Euglobulin clot lysis time - Tissue plasminogen activator - Plasminogen activator inhibitor 1

• References

• 1 Marsh M. Measurement of fibrinolysis and fibrinolytic components. In: Fibrinolysis John Wiley; New York: 1981: 206-241
• 2 Davidson JF, Walker ID. Assessment of the fibrinolytic system. In: Haemostasis and Thrombosis Bloom AL, Thomas DP. (eds). Churchill Livingstone; New York: 1987: 953-966
• 3 Brommer EJ P, Schicht I, Wijngaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemostas 1984; 52: 311-314
• 4 Rijken DC, Juhan-Vague I, DeCock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101: 274-284
• 5 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-820
• 6 Cole E, Bachmann F, Marchant L. Plasminogen activators from porcine tissues: enzymatic and immunologic properties. In: Progress in Chemical Fibrinolysis and Thrombolysis Vol. 3 Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds). Raven Press; New York: 1978: 99-106
• 7 Kluft C. Levels of plasminogen activators in human plasma: new methods to study the intrinsic and extrinsic activators. In: Progress in Chemical Fibrinolysis and Thrombolysis Vol. 3 Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds) Raven Press; New York: 1978: 141-154
• 8 Kluft C, Jie AF H, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-332
• 9 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744
• 10 Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 1988; 262: 199-210
• 11 Kruithof EK O, Chien TT, Bachman F. The fast acting inhibitor of tissue plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemostas 1986; 55: 65-69
• 12 Chmielewska J, Rånby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Evidence for “second-site” interactions. Biochem J 1988 251. 327-332
• 13 Takada Y, Takada A. Measurement of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma. Thromb Res 1988; (Suppl. 08) 15-22
• 14 Rydzewski A, Takada Y, Takada A. Determination of plasminogen activator inhibitor-1 (PAI-1) in plasma using two different anticoagulants and methods. Thromb Res 1989; 55: 285-289
• 15 Takada A, Shizume K, Ozawa T, Takahashi S, Takada Y. Characterization of various antibódies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 1986; 42: 63-72
• 16 Wun T-C, Palmier MO, Siegel NR, Smith CE. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinasc. J. Biol Chcm 1989; 264: 7862-7868
• 17 Urano S, Metzger AR, Castellino FJ. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators. Proc Natl Acad Sci USA 1989; 86: 2568-2571
• 18 Carlson RH, Garnick RL, Jones AJ S, Meunier AM. The determination of recombinant human tissue type plasminogen activator by turbidimetry using a microcentrifugal analyzer. Anal Biochem 1988; 168: 428-435
• 19 Wijngaards G. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Thromb Haemostas 1979; 41: 590-600
• 20 Nicoloso G, Hauert J, Kruithof EK O, Melle GV, Bachmann F. Fibrinolysis in normal subjects – comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemostas 1988; 59: 299-303
• 21 Gaffney PJ. Fibrinolysis. In: Haemostasis and Thrombosis Bloom AL, Thomas DP. (eds). Churchill Livingstone; New York: 1987: 223-244